As an essential health care service provider, the American Red Cross must remain operational. Throughout the COVID-19 pandemic the Red Cross has developed protocols to keep donors and staff safe and maintain continuity of operations. We have provided uninterrupted support of our clients research and commercial needs throughout this challenging period. We continue to be in regular contact with regulators to monitor any changes, and we follow FDA, AABB, and FACT guidance related to the collection of HCT/P products.
There is currently no data or evidence that COVID-19 can be transmitted by blood transfusion or transfer of HCT/Ps. Thus, aside from the additional screening measures to identify and defer potential donors who may have a COVID-19 infection, the collection of clinical-grade Leukopaks has not been impacted by the COVID-19 pandemic.
To ensure continuity of life-saving products and services during the pandemic, we acted quickly in early March 2020 to implement a standardized response plan and protocols at all our collection sites nationwide. This robust and dynamic approach ensures that we maintain the availability of repeat or unique donor raw material and allows for continued flexibility to support the development and clinical manufacture of allogeneic and autologous cell therapies through this unforeseen time.